MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Danaher Corp

Затворен

СекторЗдравеопазване

197.94 -3.52

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

197.71

Максимум

204.96

Ключови измерители

By Trading Economics

Приходи

268M

1.1B

Продажби

738M

6.5B

P/E

Средно за сектора

38.752

63.778

EPS

2.14

Дивидентна доходност

0.62

Марж на печалбата

16.611

Служители

61,000

EBITDA

-230M

1.4B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+28.05% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.62%

2.39%

Следващи печалби

22.04.2025 г.

Следваща дата на дивидент

25.04.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-16B

147B

Предишно отваряне

201.46

Предишно затваряне

197.94

Настроения в новините

By Acuity

33%

67%

106 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Danaher Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.02.2025 г., 12:54 ч. UTC

Печалби

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

29.01.2025 г., 11:44 ч. UTC

Печалби

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

22.10.2024 г., 10:35 ч. UTC

Печалби

Danaher 3Q EPS, Sales Top Views on Strong Cepheid Test Demand

23.07.2024 г., 10:55 ч. UTC

Печалби

Danaher Expects 3Q Core Sales Drop, Backs 2024 Guidance

29.01.2025 г., 15:25 ч. UTC

Пазарно говорене
Печалби

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

29.01.2025 г., 13:56 ч. UTC

Топ новини
Печалби

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

29.01.2025 г., 11:08 ч. UTC

Печалби

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

29.01.2025 г., 11:07 ч. UTC

Печалби

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

29.01.2025 г., 11:07 ч. UTC

Печалби

Danaher: Expect to Return to Growth, Build Back to Normal Market Conditions in 2025 >DHR

29.01.2025 г., 11:02 ч. UTC

Печалби

Danaher Sees 2025 Adjusted Core Revenue Up About 3% >DHR

29.01.2025 г., 11:01 ч. UTC

Печалби

Danaher Sees 1Q Adjusted Core Revenue Down Low-Single Digits >DHR

29.01.2025 г., 11:01 ч. UTC

Печалби

Danaher 4Q Operating Cash Flow $2B, Free Cash Flow $1.5B >DHR

29.01.2025 г., 11:00 ч. UTC

Печалби

Danaher 4Q Adjusted Core Revenue Rose 1% >DHR

29.01.2025 г., 11:00 ч. UTC

Печалби

Danaher 4Q Cont Ops EPS $1.49 >DHR

29.01.2025 г., 11:00 ч. UTC

Печалби

Danaher 4Q Net $1.09B >DHR

29.01.2025 г., 11:00 ч. UTC

Печалби

Danaher 4Q EPS $1.49 >DHR

29.01.2025 г., 11:00 ч. UTC

Печалби

Danaher 4Q Adj EPS $2.14 >DHR

29.01.2025 г., 11:00 ч. UTC

Печалби

Danaher 4Q Sales $6.5B >DHR

22.10.2024 г., 10:02 ч. UTC

Печалби

Danaher 3Q Adjusted Core Revenue Rose 0.5% >DHR

22.10.2024 г., 10:02 ч. UTC

Печалби

Danaher Still Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

22.10.2024 г., 10:01 ч. UTC

Печалби

Danaher Sees 4Q Adjusted Core Revenue Down Low-Single Digits >DHR

22.10.2024 г., 10:00 ч. UTC

Печалби

Danaher 3Q Operating Cash Flow $1.5B, Adjusted Free Cash Flow $1.2B >DHR

22.10.2024 г., 10:00 ч. UTC

Печалби

Danaher 3Q Sales $5.8B >DHR

22.10.2024 г., 10:00 ч. UTC

Печалби

Danaher 3Q EPS $1.12 >DHR

22.10.2024 г., 10:00 ч. UTC

Печалби

Danaher 3Q Adj EPS $1.71 >DHR

22.10.2024 г., 10:00 ч. UTC

Печалби

Danaher 3Q Net $818M >DHR

22.10.2024 г., 10:00 ч. UTC

Печалби

Danaher 3Q Cont Ops EPS $1.12 >DHR

23.07.2024 г., 12:39 ч. UTC

Топ новини
Печалби

Danaher Stock Surges. More Than Earnings Are Driving It Higher. -- Barrons.com

23.07.2024 г., 10:05 ч. UTC

Печалби

Danaher 2Q Adjusted Core Revenue Fell 3.5% >DHR

23.07.2024 г., 10:05 ч. UTC

Печалби

Danaher Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

Сравнение с други в отрасъла

Ценова промяна

Danaher Corp Прогноза

Ценова цел

By TipRanks

28.05% нагоре

12-месечна прогноза

Среден 262.71 USD  28.05%

Висок 300 USD

Нисък 240 USD

Според 17 анализатори от Wall Street, предложили 12-месечна ценова цел за Danaher Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

17 ratings

13

Купи

4

Задържане

0

Продай

Техническа оценка

By Trading Central

199.78 / 210.26Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

106 / 386 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.